Table 1.

Response rate, survival and adverse events in nivolumab trials.

	Topalian et al. 2014 (JCO)	Weber et al. 2013 (JCO)		Wolchok et al. 2013 (NEJM)
		Ipilimumab naïve	Ipilimumab refractory	Ipilimumab + Nivolumab concurrent therapy
Patient number	107	34	56	53
Objective response rate (%)	31%	24%	26%	40%
PDL-1 positive (%)*	36	67		46
PDL-1 negative (%)	0	19		41
Overall survival at 12 months	62%	–		85%
Grade 3/4 treatment related adverse events (%)	5	9	5	53

^*Cutoff of 5% staining by IHC.

UHC, immunohistochemistry; PD-L1, programmed death ligand-1.